Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by MrMugsyon Sep 17, 2021 10:49pm

123 Views

Post# 33882547

Regular Ownership Plan for Samira ...

There's going to be a nice accumulation right here for Samira on a monthly basis.
Don't think she'll need to do much else to start accumulating at a nice clip.

Filed 2021-09-17 17:47 Tx date 2021-09-15	$GUD Knight Therapeutics Inc.	Sakhia, Samira 4 - Director of Issuer, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 30 - Acquisition or disposition under a purchase/ownership plan	$12,754 +2,402 vol $5.31 each	60,486
Filed 2021-09-17 17:44 Tx date 2021-09-15	$GUD Knight Therapeutics Inc.	Utchanah, Arvind 5 - Senior Officer of Issuer Direct Ownership	Common Shares 30 - Acquisition or disposition under a purchase/ownership plan	$4,651 +876 vol $5.31 each	9,313
Filed 2021-09-17 17:43 Tx date 2021-09-15	$GUD Knight Therapeutics Inc.	Khouri, Amal 5 - Senior Officer of Issuer Direct Ownership	Common Shares 30 - Acquisition or disposition under a purchase/ownership plan	$10,535 +1,984 vol $5.31 each	120,018
Filed 2021-09-17 17:40 Tx date 2021-09-15	$GUD Knight Therapeutics Inc.	Goodman, Jonathan Ross 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder Direct Ownership	Common Shares 30 - Acquisition or disposition under a purchase/ownership plan	$10,598 +1,996 vol $5.31 each	636,184